Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Bazedoxifene Plus Conjugated Estrogens for Hot Flashes in Women at High Risk for Breast Cancer
Glossary on
off
Printer Friendly Page Bazedoxifene Plus Conjugated Estrogens for Hot Flashes in Women at High Risk for Breast Cancer

Bazedoxifene Plus Conjugated Estrogens for Hot Flashes in Women at High Risk for Breast Cancer

Clinicaltrials.gov identifier:
NCT04821141

Quality of Life
Women at high risk for breast cancer due to ATM, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, STK11, P53 or PTEN mutation who have hot flashes

Study Contact Information:

Amy L Kreutzjans, [email protected]
Bruce F Kimler, PhD: 913-205-6382: [email protected]   
Contact: Carol J Fabian, MD: 913-588-7791: [email protected]   

Study of Oral Drug Bazedoxifene Plus Conjugated Estrogens for Treating Hot Flashes in Women at High Risk for Breast Cancer

About the Study

Bazedoxifene is a type of drug known as a selective receptor modulator (SERM) that is similar to the drug tamoxifen. A combination of bazedoxifene and taken orally has been used to control hot flashes. This study will look at hot flashes, quality of life and breast changes in high-risk women taking the combination of drugs compared with women not taking the combination of drugs. The study will involve breast imaging, blood tests and small sampling of breast tissue at the beginning and end of the study. 

What the Study Involves

Participants will be selected at random and assigned to one of two groups. 

  • Group 1 will receive the drugs bazedoxifene and taken together orally once daily for 6 months. 
  • Group 2 will not receive the drug combination for 6 months. After 6 months, participants in this group will have the option to begin taking the medications. 

Participants will be asked to undergo the following tests at baseline and 6 months: 

  • fine needle aspiration of breast tissue to measure biomarkers
  • breast imaging
  • blood tests for biomarkers

Study Sites

California

  • Duarte
    City of Hope Medical Center
    Lead researchers: Victoria Seewaldt, MD; Lisa Yee, MD
  • San Francisco
    University of California San Francisco
    Lead researcher: Laura Esserman, MD

Illinois

  • Chicago
    Northwestern Medical Center
    Lead Researcher: Sema Khan, MD    

Kansas

Massachusetts

  • Boston
    Dana-Farber Cancer Institute
    Lead researcher: Judy Garber, MD
This Study is Open To:

Women, ages 45-60, who meet the following may be eligible:

  • Current symptoms of hot flashes, night sweats, or both. These do not need to be frequent or severe but should occur at least once a week.
  • Must be in one of the four menopausal status categories (below):
    • age 45-60 with an intact uterus and no periods in the past 12 months. 
    • age 45-60 with an intact uterus and no periods in the past 2 months prior to eligibility testing for this study. 
    • age 50-60 and prior hysterectomy, prior endometrial ablation with subsequent lack of periods, or menses suppression due to Mirena IUD or other contraceptives. 
    • age 45-59 and prior hysterectomy, prior endometrial ablation with subsequent lack of periods, or menses suppression due to Mirena IUD or other contraceptives.  A pre-study follicle-stimulating hormone (FSH) test must be in postmenopausal range.
  • must have at least one ovary.
  • BMI: ≤ 35 kg/m2.
  • must have at least one breast which hasn't received radiation treatment.
  • Moderate risk of developing breast cancer based on having at least one of the following:
    • women with known gene mutations associated with an increased risk for breast cancer such as , , , , , , , , P53 (Note: BRCA1/2 are excluded as women 45 and over should have undergone risk-reducing salpingo-oophorectomy).
    • first or second degree relative with breast cancer age 60 or younger.
    • a prior breast biopsy showing proliferative breast disease, or 2 or more prior biopsies regardless of benign histology.
    • 10-year of ≥2X that for the average population for age group as calculated by a risk-assessment tool. 
  • vaginal hormones: low dose vaginal hormones, such as Estring(®, Vagifem®, Imvexy®, or 0.5 gram or less of conjugated vaginal cream twice weekly or less often may be continued at the same dose.
  • systemic hormones: if previously on oral contraceptives or systemic hormone replacement, must be off for 8 weeks or more.

Contact study team for full eligibility and ineligibility.

This Study is Not Open To:

People with the following may not participate: 

  • increased risk or previous history of blood clots.
  • have had both ovaries removed. 
  • have a or inherited mutation.
  • have been diagnosed with , , or invasive breast cancer, uterine cancer or ovarian cancer.
  • abnormal liver and kidney function tests.

Medications

  • must discontinue anticoagulant use (must have discontinued for 3 weeks before breast fine needle aspirate. 
  • taking tamoxifen, raloxifene, or an aromatase inhibitor within 6 months of baseline blood imaging or needle aspirate.

Willing to comply with study procedures.

  • fasting blood drawn at baseline and 6 months.
  • dual energy x-ray absorptiometry (iDXA) at baseline and 6 months (at KUMC only).
  • repeat and RPFNA at 6 months following initiation of study drug. (12-month for waitlist control only is optional)
  • must be willing to use non-hormonal contraceptive precautions.

Contact study team for full eligibility and ineligibility.